NASDAQ:ACER - Acer Therapeutics Stock Price, News, & Analysis

Sign in or create an account to add this stock to your watchlist.
$23.78 -0.17 (-0.71 %)
(As of 02/20/2019 04:00 PM ET)
Previous Close$23.95
Today's Range$23.40 - $24.00
52-Week Range$16.02 - $34.10
Volume21,852 shs
Average Volume26,243 shs
Market Capitalization$231.12 million
P/E Ratio-6.19
Dividend YieldN/A
Beta2.61
Acer Therapeutics Inc., a pharmaceutical company, develops therapies for the treatment of rare diseases with critical unmet medical needs. Its product candidates include Celiprolol for the treatment of vascular Ehlers-Danlos syndrome; and ACER-001 for the treatment of urea cycle disorders and maple syrup urine disease. The company was founded in 2013 and is headquartered in Newton, Massachusetts.

Receive ACER News and Ratings via Email

Sign-up to receive the latest news and ratings for ACER and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:ACER
CUSIPN/A
Phone844-902-6100

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$2.90 million
Book Value$3.03 per share

Profitability

Net Income$-14,190,000.00

Miscellaneous

Employees6
Market Cap$231.12 million
OptionableNot Optionable

Acer Therapeutics (NASDAQ:ACER) Frequently Asked Questions

What is Acer Therapeutics' stock symbol?

Acer Therapeutics trades on the NASDAQ under the ticker symbol "ACER."

How were Acer Therapeutics' earnings last quarter?

Acer Therapeutics Inc (NASDAQ:ACER) posted its quarterly earnings results on Monday, November, 12th. The biopharmaceutical company reported ($0.43) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.53) by $0.10. View Acer Therapeutics' Earnings History.

When is Acer Therapeutics' next earnings date?

Acer Therapeutics is scheduled to release their next quarterly earnings announcement on Wednesday, March 6th 2019. View Earnings Estimates for Acer Therapeutics.

What price target have analysts set for ACER?

5 equities research analysts have issued 12-month target prices for Acer Therapeutics' stock. Their predictions range from $40.00 to $70.00. On average, they expect Acer Therapeutics' share price to reach $53.25 in the next year. This suggests a possible upside of 123.9% from the stock's current price. View Analyst Price Targets for Acer Therapeutics.

What is the consensus analysts' recommendation for Acer Therapeutics?

5 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Acer Therapeutics in the last year. There are currently 5 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Acer Therapeutics.

What are Wall Street analysts saying about Acer Therapeutics stock?

Here are some recent quotes from research analysts about Acer Therapeutics stock:
  • 1. According to Zacks Investment Research, "Acer Therapeutics Inc. is a pharmaceutical company. It develops therapies for the treatment of ultra-rare diseases with critical unmet medical need. The company's product pipeline consists of Edsivo (TM) and ACER-001 which are in clinical stage. Acer Therapeutics Inc., formerly known as Opexa Therapeutics, Inc., is based in Cambridge, United States. " (2/5/2019)
  • 2. HC Wainwright analysts commented, "Valuation methodology, risks, and uncertainties. We value Acer using a composite risk-adjusted net present value (rNPV) approach, which employs a 15% discount rate and 30% effective tax rate across all future cash flows, while ascribing an 85% probability of success to EDSIVO and a 60% and 50% probability of success to MSUD, respectively. This yields a total rNPV of $600M, with $350M coming from EDSIVO and $250M from ACER-001. Assuming approximately 11M fully-diluted shares outstanding as of mid-2019, this translates into a price objective of $55.00 per share." (12/27/2018)

Has Acer Therapeutics been receiving favorable news coverage?

News stories about ACER stock have been trending neutral this week, according to InfoTrie Sentiment. The research firm ranks the sentiment of news coverage by monitoring more than six thousand blog and news sources in real time. The firm ranks coverage of companies on a scale of -5 to 5, with scores nearest to five being the most favorable. Acer Therapeutics earned a media sentiment score of 0.3 on InfoTrie's scale. They also gave news headlines about the biopharmaceutical company a news buzz of 5.0 out of 10, meaning that recent news coverage is somewhat likely to have an impact on the stock's share price in the next several days.

Who are some of Acer Therapeutics' key competitors?

Who are Acer Therapeutics' key executives?

Acer Therapeutics' management team includes the folowing people:
  • Mr. Christopher Schelling, Founder, Pres, CEO & Director (Age 43)
  • Mr. Harry S. Palmin, COO & CFO (Age 49)
  • Dr. William T. Andrews M.D., FACP, Chief Medical Officer (Age 54)
  • Mr. Donald R. Joseph, Chief Legal Officer & Sec. (Age 65)
  • Ms. Jeannie Kim, VP of Corp. Devel.

Who are Acer Therapeutics' major shareholders?

Acer Therapeutics' stock is owned by a variety of of institutional and retail investors. Top institutional investors include Nantahala Capital Management LLC (9.30%), venBio Select Advisor LLC (1.54%), Geode Capital Management LLC (0.37%), Northern Trust Corp (0.35%), Barclays PLC (0.26%) and Fosun International Ltd (0.16%). Company insiders that own Acer Therapeutics stock include Life Science Ventures Vii Tvm and Steve Aselage. View Institutional Ownership Trends for Acer Therapeutics.

Which institutional investors are selling Acer Therapeutics stock?

ACER stock was sold by a variety of institutional investors in the last quarter, including venBio Select Advisor LLC and BlackRock Inc.. View Insider Buying and Selling for Acer Therapeutics.

Which institutional investors are buying Acer Therapeutics stock?

ACER stock was acquired by a variety of institutional investors in the last quarter, including Nantahala Capital Management LLC, Barclays PLC, Fosun International Ltd, Geode Capital Management LLC, First Manhattan Co., Northern Trust Corp and Bank of Montreal Can. Company insiders that have bought Acer Therapeutics stock in the last two years include Life Science Ventures Vii Tvm and Steve Aselage. View Insider Buying and Selling for Acer Therapeutics.

How do I buy shares of Acer Therapeutics?

Shares of ACER can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Acer Therapeutics' stock price today?

One share of ACER stock can currently be purchased for approximately $23.78.

How big of a company is Acer Therapeutics?

Acer Therapeutics has a market capitalization of $231.12 million and generates $2.90 million in revenue each year. The biopharmaceutical company earns $-14,190,000.00 in net income (profit) each year or ($3.84) on an earnings per share basis. Acer Therapeutics employs 6 workers across the globe.

What is Acer Therapeutics' official website?

The official website for Acer Therapeutics is http://www.acertx.com.

How can I contact Acer Therapeutics?

Acer Therapeutics' mailing address is 300 WASHINGTON STREET SUITE 351, NEWTON MA, 02458. The biopharmaceutical company can be reached via phone at 844-902-6100 or via email at [email protected]


MarketBeat Community Rating for Acer Therapeutics (NASDAQ ACER)

Community Ranking:  2.8 out of 5 (star star)
Outperform Votes:  192 (Vote Outperform)
Underperform Votes:  152 (Vote Underperform)
Total Votes:  344
MarketBeat's community ratings are surveys of what our community members think about Acer Therapeutics and other stocks. Vote "Outperform" if you believe ACER will outperform the S&P 500 over the long term. Vote "Underperform" if you believe ACER will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 2/20/2019 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel